Genzyme in the UK

Company Info

Genzyme Welcomes Publication of UK Strategy for Rare Disease

Date: November 22, 2013

Oxford, UK. – Genzyme, a Sanofi company, welcomes today’s publication of the UK Strategy for Rare Diseases by the UK Government. The new strategy is intended to: empower patients affected by rare conditions; identify and prevent rare conditions; and improve diagnosis and early intervention. The new strategy also recognises the need for coordinated care for patients with rare diseases and the importance of scientific research.

The UK Strategy for Rare Diseases has been developed with input from Rare Disease UK in response to a Recommendation of the Council of the European Union for each EU member state to have in place a rare diseases plan by the end of 2013. The UK Government will now work with the health departments in the devolved nations and local branches of Rare Disease UK to ensure the ambitions of the Strategy are achieved. Separate plans for England, Scotland, Wales and Northern Ireland are expected to be published early next year.

Brendan Martin, General Manager UK & Ireland, Genzyme, said: “Genzyme has been developing and delivering transformative therapies for very rare diseases for over 30 years. Today’s publication of a UK-wide strategy is an important step in ensuring that patients affected by rare and complex conditions have the best possible care and are properly served by the NHS. The strategy now needs to be implemented fully in all four nations and backed by a commitment to provide innovative therapies to patients as they become available through advances in medical research.”

Genzyme has a long history in rare diseases and is known for its expertise in Lysosomal Storage Disorders (LSDs) a group of rare genetic conditions caused by enzyme deficiencies. In 1984, Genzyme developed the first enzyme replacement therapy to treat Gaucher disease and has since launched treatments for Fabry disease, MPS I, and Pompe disease.

Genzyme is continuing to develop drugs for LSDs that currently have limited treatment options and to apply its expertise to new forms of treatment delivery, such as oral therapies, that are more convenient for patients than intravenous enzyme infusions.

About Rare Disease

Rare Disease UK (RDUK) is the national alliance for people with rare diseases and all who support them. Its membership is open to all and includes patient organisations, clinicians, researchers, academics, industry and individuals with an interest in rare diseases.

RDUK was established by Genetic Alliance UK, the national charity of over 160 patient organisations supporting all those affected by genetic conditions, in conjunction with other key stakeholders in November 2008 following the European Commission’s ‘Communication on Rare Diseases: Europe’s Challenges’. www.raredisease.org.uk

About Genzyme in the UK

Genzyme is a significant force in the UK biotechnology sector focused on improving the lives of patients with rare genetic diseases and multiple sclerosis. First established in the UK in 1981, Genzyme employs 450 people at two sites. Genzyme Therapeutics in Oxford is the company’s UK commercial base marketing products for the treatment of patients with chronic debilitating diseases. These include genetic diseases such as lysosomal storage disorders (LSDs) – characterised by a lack of enzymes essential to healthy biological processes – and multiple sclerosis – a complex neurological disease affecting the central nervous system. Our portfolio also includes a therapy which aids in the management of thyroid cancer.

Genzyme’s manufacturing facility in Haverhill, Suffolk has undergone a dramatic building programme since its purchase in 1982 and now employs 380 people at a site with two large-scale manufacturing plants, a pilot plant, a development centre, warehouse and other associated facilities. Genzyme’s Haverhill facility manufactures the active ingredients in therapies for patients undergoing renal dialysis and is a major global distribution centre for Genzyme’s products for genetic diseases. Learn more at www.genzyme.co.uk

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through worldclass research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme® is a registered trademark. All rights reserved

Highlight

  • Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

    Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. Read the full corporate press release.

Contact Info:

Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Oxford
OX4 2SU
Tel: +01865 405200
Fax: +01865 774172
Email

Contact Info:

Genzyme Ltd, Haverhill Operations
12 Rookwood Way
Haverhill
Suffolk
CB9 8PU
Tel: +01440 703522
Fax: +01440 716269

'